Tom Wilemon

September 13, 2022

Patients had ‘significant and clinically meaningful improvement’ in survival in fruquintinib clinical trial

Patients with metastatic colorectal cancer who had not responded to other treatments had “significant and clinically meaningful improvement” in overall survival when treated with the oral targeted therapy fruquintinib.

By Tom Wilemon
Eunyoung Choi, PhD, James Goldenring, MD, PhD, and colleagues are studying the development of cancer in the stomach and esophagus.
September 1, 2022

Grant supports research to study gastric cancer origins

Vanderbilt researchers have received $5 million in funding from a new initiative by the National Cancer Institute that aims to define how gastric and gastroesophageal junction adenocarcinomas form and evolve at the cellular level.

By Tom Wilemon
September 1, 2022

Chic Aweareness ovarian cancer fundraiser moves online

Chic Awearness, a fundraiser for ovarian cancer research at Vanderbilt-Ingram Cancer Center (VICC), is an online event this year from now throughout September with an in-store shopping opportunity to close out the month called Chic Week.

By Tom Wilemon
August 18, 2022

Abramson, Eng, Johnson named to new VICC roles

Three physician researchers at Vanderbilt-Ingram Cancer Center are assuming additional leadership roles.

By Tom Wilemon
August 17, 2022

Trial for colorectal cancer drug reaches primary endpoint

A new therapy for metastatic colorectal cancer that has been granted fast track designation by the U.S. Food and Drug Administration has met its primary endpoint of overall survival in a phase 3 clinical trial.

By Tom Wilemon
Luke and Susan Simons recently made a gift to establish the Susan and Luke Simons Directorship at Vanderbilt-Ingram Cancer Center.
August 11, 2022

Couple’s gift helps support immunotherapy research

Luke and Susan Simons have endowed a new directorship that will support research so that more people can benefit from immunotherapies.

By Tom Wilemon
August 5, 2022

Study that investigated whether three smoking cessation drugs could reduce alcohol intake yields unexpected finding

A Vanderbilt study of three proven smoking cessation treatments suggests these medications could play an important role to reduce alcohol use and smoking at the same time.
By Tom Wilemon
July 28, 2022

Study reveals need for matching targeted therapies with EGFR subtypes

A Vanderbilt study suggests that clinicians should take a deeper dive into distinguishing EGFR mutations when prescribing targeted therapies for non-small-cell lung cancers.
By Tom Wilemon
July 15, 2022

Holowatyj named chair of scientific advisory board for ACPMP Research Foundation

Vanderbilt's Andreana Holowatyj, PhD, MSCI, has been named the inaugural chair of the scientific advisory board for the Appendix Cancer Pseudomyxoma Peritonei Research Foundation.
By Tom Wilemon
June 28, 2022

Smokers have better quit rates with hospital-based interventions than quitline help, but study indicates need for longer follow-up

A health care system model that offered tobacco cessation treatment to smokers being discharged from a hospital produced a higher rate of tobacco abstinence during the three-month program than referral to a state-based telephone quitline, but the advantage disappeared at six months when both treatments produced comparable quit rates, researchers have found.
By Tom Wilemon
June 23, 2022

Study reveals how gastric cancer forms, suggests preventive treatment

Eunyoung Choi, PhD, assistant professor of Surgery, and colleagues identified for the first time that Trop2+/CD133+/CD166+ dysplastic stem cells are a key source of clonal evolution of dysplasia to multiple types of gastric cancer.
By Tom Wilemon
June 2, 2022

Choi, Short receive AGA Research Foundation Awards

Two Vanderbilt researchers have received awards from the AGA Foundation, the charitable arm of the American Gastroenterological Association.
By Tom Wilemon
1 … 5 6 7 8 9 … 35